Sirsi Deepa, Safdieh Joseph E
Weill Medical College of Cornell University, Division of Child Neurology, NY 10021, USA.
Expert Opin Drug Saf. 2007 May;6(3):241-50. doi: 10.1517/14740338.6.3.241.
Levetiracetam is an antiepileptic drug approved for use as an adjunct agent in partial-onset seizures in adults and children aged > or = 4 years. It was also approved as adjunctive therapy in the treatment of adults and adolescents aged > or = 12 years with juvenile myoclonic epilepsy. A parenteral intravenous formulation has recently become available allowing for its use when oral administration is temporarily not feasible. Available literature has demonstrated and supported that levetiracetam has an acceptable safety profile and this review discusses the safety profile of levetiracetam, with attention to special populations. The most common adverse effects are somnolence, asthenia and dizziness, which usually appear early after initiation of levetiracetam therapy and generally resolve without medication withdrawal. The most serious adverse effects are behavioral in nature and are more common in children and in patients with a prior history of behavioral problems.
左乙拉西坦是一种抗癫痫药物，被批准作为辅助药物用于治疗4岁及以上成人和儿童的部分性发作。它还被批准作为辅助疗法用于治疗12岁及以上患有青少年肌阵挛性癫痫的成人和青少年。最近有一种肠胃外静脉注射制剂可供使用，当暂时无法进行口服给药时可以使用。现有文献已经证明并支持左乙拉西坦具有可接受的安全性，本综述讨论了左乙拉西坦的安全性，特别关注特殊人群。最常见的不良反应是嗜睡、乏力和头晕，这些通常在开始左乙拉西坦治疗后早期出现，一般无需停药即可缓解。最严重的不良反应本质上是行为方面的，在儿童和有行为问题既往史的患者中更常见。
